JARID2 and hepatocellular carcinoma: We found that high expressions of ARID1A, ARID1B, ARID3A, ARID2, ARID3B, ARID5A, ARID5B, and JARID2 predicted a shorter overall survival in HCC patients (Figures 3(a)–3(c)), while overall survival was reduced in patients with high ARID3C expression compared to low ARID3C expression.